Biomolecules & Therapeutics

The Korean Society of Applied Pharmacology (한국응용약물학회)
권호 표지
DOI QR코드

DOI QR Code

YH18968, a Novel 1,2,4-Triazolone G-Protein Coupled Receptor 119 Agonist for the Treatment of Type 2 Diabetes Mellitus

  • Han, Taedong (Department of Applied Chemistry and Global Center for Pharmaceutical Ingredient Materials, Kyung Hee University) ;
  • Lee, Byoung Moon (Yuhan R&D Institute) ;
  • Park, Yoo Hoi (Yuhan R&D Institute) ;
  • Lee, Dong Hoon (Yuhan R&D Institute) ;
  • Choi, Hyun Ho (Yuhan R&D Institute) ;
  • Lee, Taehoon (Department of Applied Chemistry and Global Center for Pharmaceutical Ingredient Materials, Kyung Hee University) ;
  • Kim, Hakwon (Department of Applied Chemistry and Global Center for Pharmaceutical Ingredient Materials, Kyung Hee University)
  • Received : 2018.01.22
  • Accepted : 2018.01.29
  • Published : 2018.03.01
Download PDF
⟨ Previous Next ⟩

Abstract

G protein-coupled receptor 119 (GPR119) is expressed in the pancreas and gastrointestinal tract, and its activation promotes insulin secretion in the beta cells of the pancreatic islets as well as the secretion of glucagon-like peptide-1 (GLP-1) in intestinal L cells, consequently improving glucose-stimulated insulin secretion. Due to this dual mechanism of action, the development of small-molecule GPR119 agonists has received significant interest for the treatment of type 2 diabetes. We newly synthesized 1,2,4-triazolone derivatives of GPR119 agonists, which demonstrated excellent outcomes in a cyclic adenosine monophosphate (cAMP) assay. Among the synthesized derivatives, YH18968 showed cAMP=2.8 nM; in GLUTag cell, GLP-1secretion=2.3 fold; in the HIT-T15 cell, and insulin secretion=1.9 fold. Single oral administration of YH18968 improved glucose tolerance and combined treatment with a dipeptidyl peptidase 4 (DPP-4) inhibitor augmented the glucose lowering effect as well as the plasma level of active GLP-1 in normal mice. Single oral administration of YH18968 improved glucose tolerance in a diet induced obese mice model. This effect was maintained after repeated dosing for 4 weeks. The results indicate that YH18968 combined with a DPP-4 inhibitor may be an effective therapeutic candidate for the treatment of type 2 diabetes.

Keywords

References

  1. Bailey, C. J. (2008) Metformin: effects on micro and macrovascular complications in type 2 diabetes. Cardiovasc. Drugs Ther. 22, 215-224. https://doi.org/10.1007/s10557-008-6092-0
  2. Blad, C. C., Tang, C. and Offermanns, S. (2012) G protein-coupled receptors for energy metabolites as new therapeutic targets. Nat. Rev. Drug Discov. 11, 603-619. https://doi.org/10.1038/nrd3777
  3. Chu, Z. L., Jones, R. M., He, H., Carroll, C., Gutierrez, V., Lucman, A., Moloney, M., Gao, H., Mondala, H., Bagnol, D., Unett, D., Liang, Y., Demarest, K., Semple, G., Behan, D. P. and Leonard, J. (2007) A role for beta-cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release. Endocrinology 148, 2601-2609. https://doi.org/10.1210/en.2006-1608
  4. Cornall, L. M., Hryciw, D. H., Mathai, M. L. and McAinch, A. J. (2015) Direct activation of the proposed anti-diabetic receptor, GPR119 in cardiomyoblasts decreases markers of muscle metabolic activity. Mol. Cell Endocrinol. 402, 72-85.
  5. Cusi, K., Consoli, A. and DeFronzo, R. A. (1996) Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. J. Clin. Endocrinol. Metab. 81, 4059-4067.
  6. DeFronzo, R. A., Bonadonna, R. C. and Ferrannini, E. (1999) Pathogenesis of NIDDM. A balanced overview. Diabetes Care. 15, 318-368.
  7. DeFronzo, R. A. (2009) Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 58, 773-795.
  8. Drucker, D. J. (1998) Glucagon-like peptide. Diabetes 47, 159-169.
  9. Han, T. D., Jung, E. H., Yi, C. H., Lee, B. M., Park, Y. H., Lee, D. H., Kang, J. H., Yang, N. Y., Kim, D. H., Hyun, K. H., Park, K. J., Lee, C. H. and Nam, S. H. (2014) Novel triazolone derivatives or salts thereof and pharmaceutical composition comprising the same. PCT International applications WO2014175621 A1. 2014 Apr 22.
  10. Hothersall, J. D., Bussey, C. E., Brown, A. J., Scott, J. S., Dale, I. and Rawlins, P. (2015) Sustained wash-resistant receptor activation response of GPR119 agonist. Eur. J. Pharmacol. 762, 430-442. https://doi.org/10.1016/j.ejphar.2015.06.031
  11. Jones, R. M., Leonard, J. N., Buzard, D. J. and Lehmann, J. (2009) GPR119 agonists for the treatment of type 2 diabetes. Expert Opin. Ther. Pat. 19, 1339-1359. https://doi.org/10.1517/13543770903153878
  12. Katz, L. B., Gambale, J. J., Rothenberg, P. L., Vanapalli, S. R., Vaccaro, N., Xi, L., Polidori, D. C., Vets, E., Sarich, T. C. and Stein, P. P. (2011) Pharmacokinetics, pharmacodynamics, safety, and tolerability of JNJ-38431055, a novel GPR119 receptor agonist and potential antidiabetes agent, in healthy male subjects. Clin. Pharmacol. Ther. 90, 685-692.
  13. Katz, L. B., Gambale, J. J., Rothenberg, P. L., Vanapalli, S. R., Vaccaro, N., Xi, L., Sarich, T. C. and Stein, P. P. (2012) Effects of JNJ-38431055, a novel GPR119 receptor agonist, in randomized, double-blind, placebo-controlled studies in subjects with type 2 diabetes. Diabetes Obes. Metab. 14, 709-716. https://doi.org/10.1111/j.1463-1326.2012.01587.x
  14. Koro, C. E., Bowlin, S. J., Bourgeois, N. and Fedder, D. O. (2004) Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes. Diabetes Care 27, 17-20. https://doi.org/10.2337/diacare.27.1.17
  15. Lauffer, L., Iakoubov, R., Brubaker, P. L. (2008) GPR119: "double-dipping" for better glycemic control. Endocrinology 149, 2035-2037. https://doi.org/10.1210/en.2008-0182
  16. Lauffer, L. M., Iakoubov, R., Brubaker, P. L. (2009) GPR119 is essential for oleoylethanolamide-induced glucagon-like peptide-1 secretion from the intestinal enteroendocrine L-cell. Diabetes 58, 1058-1066. https://doi.org/10.2337/db08-1237
  17. Morales, J. (2011) The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors. Postgrad. Med. 123, 189-201. https://doi.org/10.3810/pgm.2011.11.2508
  18. Nesto, R. W., Bell, D., Bonow, R. O., Fonseca, V., Grundy, S. M., Horton, E. S., Le Winter, M., Porte, D., Semenkovich, C. F., Smith, S. and Young, L. H. and Kahn, R. (2003) Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation 108, 2941-2948.
  19. Nilsson, C., Raun, K., Yan, F. F., Larsen, M. O. and Tang-Christensen, M. (2012) Laboratory animals as surrogate models of human obesity. Acta Pharmacol. Sin. 33, 173-181. https://doi.org/10.1038/aps.2011.203
  20. Nunez, D. J., Bush, M. A., Collins, D. A., McMullen, S. L., Gillmor, D., Apseloff, G., Atiee, G., Corsino, L., Morrow, L. and Feldman, P. L. (2014) Gut hormone pharmacology of a novel GPR119 agonist (GSK1292263), metformin, and sitagliptin in type 2 diabetes mellitus: results from two randomized studies. PLoS ONE 9, e92494. https://doi.org/10.1371/journal.pone.0092494
  21. Overton, H. A., Babbs, A. J., Doel, S. M., Fyfe, M. C., Gardner, L. S., Griffin, G., Jackson, H. C., Procter, M. J., Rasamison, C. M., Tang-Christensen, M., Widdowson, P. S., Williams, G. M. and Reynet, C. (2006) Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents. Cell Metab. 3, 167-175. https://doi.org/10.1016/j.cmet.2006.02.004
  22. Overton, H. A., Fyfe, M. C. and Reynet, C. (2008) GPR119, a novel G protein-coupled receptor target for the treatment of type 2 diabetes and obesity. Br. J. Pharmacol. 153 Suppl 1, S76-S81.
  23. Ritter, K., Buning, C., Halland, N., Poverlein, C. and Schwink, L. (2016) G protein-coupled receptor 119 (GPR119) agonists for the treatment of diabetes: Recent progress and prevailing challenges. J. Med. Chem. 59, 3579-3592. https://doi.org/10.1021/acs.jmedchem.5b01198
  24. Sakamoto, Y., Inoue, H., Kawakami, S., Miyawaki, K., Miyamoto, T., Mizuta, K. and Itakura, M. (2006) Expression and distribution of Gpr119 in the pancreatic islets of mice and rats: predominant localization in pancreatic polypeptide-secreting PP-cells. Biochem. Biophys. Res. Commun. 351, 474-480. https://doi.org/10.1016/j.bbrc.2006.10.076
  25. Taylor, S. I., Accili, D. and Imai, Y. (1994) Insulin resistance or insulin deficiency. Which is the primary cause of NIDDM. Diabetes 43, 735-740. https://doi.org/10.2337/diab.43.6.735
  26. UK Prospective Diabetes Study (UKPDS) Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352, 854-865. https://doi.org/10.1016/S0140-6736(98)07037-8
  27. Yip, R. G. and Wolfe, M. M. (2000) GIP biology and fat metabolism. Life Sci. 66, 91-103.

Cited by

  1. Chronic treatment of JTP‐109192, a novel G‐protein coupled receptor 119 agonist, improves metabolic abnormalities in Zucker Fatty rats vol.46, pp.10, 2019, https://doi.org/10.1111/1440-1681.13152
  2. Long-Acting Glucagon-Like Peptide-1 Receptor Agonists Suppress Voluntary Alcohol Intake in Male Wistar Rats vol.14, pp.None, 2018, https://doi.org/10.3389/fnins.2020.599646
  3. GPR119 agonists: Novel therapeutic agents for type 2 diabetes mellitus vol.113, pp.None, 2018, https://doi.org/10.1016/j.bioorg.2021.104998
  4. GPR119 agonists for the treatment of type 2 diabetes: an updated patent review (2014-present) vol.31, pp.9, 2018, https://doi.org/10.1080/13543776.2021.1921152